Search

Stage IV non-small cell lung cancer is a fatal disease, with a median survival of 14 months. Systemic chemotherapy is the most common approach. However the impact in overall survival and quality of life still a controversy. OBJECTIVES: To determine differences in overall survival and quality of life among patients with stage IV non-small cell lung cancer non-metastatic to the brain treated with best supportive care versus systemic chemotherapy. PATIENTS: From February 1990 through December 1995, 78 eligible patients were admitted with the diagnosis of stage IV non-small cell lung cancer . Patients were divided in 2 groups: Group A (n=31 -- treated with best supportive care ), and Group B (n=47 -- treated with systemic chemotherapy). RESULTS: The median survival time was 23 weeks (range 5 -- 153 weeks) in Group A and 55 weeks (range 7.4 -- 213 weeks) in Group B (p=0.0018). In both groups, the incidence of admission for IV antibiotics and need of blood transfusions were similar. Patients receiving systemic chemotherapy were also stratified into those receiving mytomycin, vinblastin, and cisplatinum, n=25 and those receiving other combination regimens (platinum derivatives associated with other drugs, n=22). Patients receiving mytomycin, vinblastin, and cisplatinum, n=25 had a higher incidence of febrile neutropenia and had their cycles delayed for longer periods of time than the other group. These patients also had a shorter median survival time (51 versus 66 weeks, p=0.005). CONCLUSION: In patients with stage IV non-small cell lung cancer, non-metastatic to the brain, chemotherapy significantly increases survival compared with best supportive care.

Background. Although an uncommon disease, male breast cancer (MBC) will be responsible for 300 deaths in 1993 in the United States. Because of the high rate of estrogen receptor positivity in males, adjuvant hormonal therapy with tamoxifen in the adjuvant setting has been used widely. Little is known about the side effects of this estrogen receptor blocker in males. Methods. The authors evaluated the side effects of adjuvant tamoxifen treatment in 24 patients (19 of whom were estrogen receptor positive) treated at the authors' institution between 1990 and 1993. Results. Fifteen (62.5%) patients reported at least one side effect. The most common side effect was a decrease in libido, which occurred in 7 (29.2%) patients; followed by weight gain, which occurred in 6 (25%) patients; hot flashes, which occurred in (5 20.8%); mood alterations, which occurred in 5 (20.8%); depression, which occurred in 4 (16.6%); insomnia, which occurred in 3 (12.5%); and deep venous thrombosis, which occurred in 1 (4.2%). Five (20.8%) patients terminated treatment with tamoxifen in less than 1 year because of these side effects. Two of these patients had decreased libido, two had hot flashes, and one suffered deep venous thrombosis. Conclusions. In contrast to female breast cancer patients, who have a 4% attrition rate to adjuvant tamoxifen treatment, MBC patients have a 20.8% attrition rate related to side effects of tamoxifen treatment.

Lung cancer is one of the main causes of cancer related deaths. Approximately three quarters of these tumors are non-small cell carcinomas. When diagnosed the majority of patients show the disease locally advanced or metastatic. The chemotherapy is the chosen therapy for patients with advanced lung cancer. The majority of published studies with chemotherapy are performed in academic centers under a strict control of research protocols. PURPOSE: The aim of this study is to evaluate the usual management of metastatic NSCLC patients outside of a clinical trial setting in three different oncologic centers in Brazil. METHODS: This is a retrospective study of patients with metastatic non-small cell lung cancer admitted for treatment in three different Cancer Centers in Brazil. 564 patients from Brazilian public heath system and private/health insurance system were considered for the present study. RESULTS: Among 564 patients in this study, 335 (59.4%) received chemotherapy. For all patients, 47 different regimens of chemotherapy were identified. The median follow-up time was eight months and the overall median survival of all patient population submitted to chemotherapy was 9.7 months. DISCUSSION: There was a great heterogeneity in the regimens of drugs to treat metastatic NSCLC patients. The overall survival was significantly better for patients treated with first line chemotherapy compared to patients that only received best supportive care. Results of prospective randomized clinical trials should be carefully analyzed before transferred to the daily clinical practice. INTRODUÇÃO: O câncer de pulmão é uma das principais causas de morte relacionadas ao câncer. Aproximadamente três quartos destes tumores são carcinoma não pequenas células. Ao diagnóstico, a maioria dos pacientes se apresenta com doença avançada localmente ou metastática. A quimioterapia é o tratamento de escolha para pacientes com câncer de pulmão em estadiamento avançado. A maioria dos estudos publicados com quimioterapia é realizada em centros acadêmicos sob controle rígido de protocolos de pesquisa. OBJETIVO: O objetivo deste estudo é avaliar os resultados do tratamento rotineiro de pacientes com carcinoma de pulmão não pequenas células metastático, fora de protocolos de pesquisa clínica em três centros oncológicos brasileiros. MÉTODO: Trata-se de um estudo retrospectivo de pacientes com câncer de pulmão não pequenas células metastático, admitidos para tratamento em três diferentes centros oncológicos no Brasil. Foram avaliados 564 pacientes neste estudo provenientes do sistema de saúde público e privado. RESULTADOS: Dentre os 564 pacientes deste estudo, 335 (59,4%) receberam quimioterapia. Considerando todos os pacientes, foram identificados 47 esquemas diferentes de quimioterapia. O tempo médio de seguimento foi de oito meses e a sobrevida global mediana de todos os pacientes submetidos à quimioterapia foi de 9,7 meses. DISCUSSÃO: Havia uma grande heterogeneidade de esquemas de drogas para o tratamento de pacientes com câncer de pulmão não pequenas células metastático. A sobrevida global foi significativamente melhor para pacientes tratados com quimioterapia de primeira linha comparado com pacientes que receberam somente tratamento de suporte clínico. Resultados de estudos clínicos prospectivos randomizados deverão ser cuidadosamente analisados antes de serem transferidos para a prática clínica diária.

INTRODUCTION: In the postmenopausal period, an average of 25% of women will present symptomatic ovarian failure requiring hormonal replacement therapy. Estrogen can relieve vasomotor symptoms. Hormonal replacement therapy is generally not recommended for breast cancer patients due to the potential risk of tumor recurrence. To answer the questions about the safety of hormonal replacement therapy in this subgroup of women, it is necessary to establish the acceptance of treatment. METHODS: Between September 1998 and February 2001, a cohort of 216 breast cancer patients were asked to complete a questionnaire. All patients had completed their treatment and were informed about survival rates after breast cancer and hormonal replacement therapy. RESULTS: Among the 216 patients, 134 (62%) would refuse hormonal replacement therapy. A hundred patients were afraid of relapse (74.6%). Adjuvant tamoxifen therapy was the only statistically significant variable (70.3% versus 29.7% p=0.003). Understanding clinical stage (p= 0.045) and type of medical assistance (private versus public , p=0.033) also seemed to influence the decision. Early stage disease (p= 0.22), type of surgical procedure (radical versus conservative, p=0.67), adjuvant chemotherapy (p=0.082) or marital status (p=0.98 ) were not statistically significant in decision making. Several patients submitted to adjuvant chemotherapy (41.6%) would accept hormonal replacement therapy under medical supervision, as did most of advanced clinical stage patients (58.3%; p=0.022). CONCLUSION: There is a high level of rejection for hormonal replacement therapy among breast cancer patients when current data on tumor cure rates, and potential risks of estrogen use is available. Adverse effects of tamoxifen in the adjuvant setting may be the reason for refusal of hormonal replacement therapy . INTRODUÇÃO: Cerca de 25% das mulheres apresentarão deficiência estrogênica sintomática necessitando terapia de reposição hormonal. A utilização de terapia de reposição hormonal diminui os sintomas vasomotores e outras morbimortalidades. A terapia de reposição hormonal geralmente não é recomendada para as pacientes com câncer de mama, devido o possível aumento no risco de recorrência. Para responder às questões sobre a segurança da terapia de reposição hormonal neste subgrupo de mulheres, é necessário estabelecer a aceitação do tratamento. MÉTODO: Entre setembro de 1998 e fevereiro de 2001, 216 pacientes foram submetidas a um questionário auto-aplicável. As pacientes haviam encerrado o tratamento antineoplásico e, receberam informações sobre as taxas de sobrevida após câncer de mama e terapia de reposição hormonal. RESULTADOS: Entre as 216 pacientes, 134(62%) não fariam terapia de reposição hormonal. Cem pacientes receavam uma recorrência (74,6%). Tamoxifeno adjuvante foi a única variável estatisticamente significativa (70,3% versus 29,7% p=0,003). Conhecimento do estádio clínico (p= 0,045) e tipo de assistência médica (privada versus pública , p=0,033) parecem influenciar a decisão. Estádio inicial (p= 0,22), tipo de cirurgia (radical versus conservadora, p=0,67), quimioterapia adjuvante (p=0,082) ou estado civil (p=0,98) não foram estatisticamente significativos. Várias pacientes submetidas à quimioterapia adjuvante (41,6%) aceitariam terapia de reposição hormonal sob supervisão médica, assim como a maioria das pacientes com doença avançada (58,3%; p=0,022). DISCUSSÃO: Foi observada uma alta taxa de rejeição à terapia de reposição hormonal entre as pacientes quando informações atualizadas sobre taxas de cura, e potenciais riscos do uso de estrógeno estão disponíveis. Efeitos adversos associados ao tamoxifeno adjuvante poderiam estar relacionados à maior recusa .

Multiple factors, both environmental and genetic, are thought to play roles in breast carcinogenesis. The recently cloned multiple tumor suppressor gene (MTS1), the product of which interacts with CDK4 to regulate cell growth, has been found to be mutated with high frequency in a variety of cell lines as well as primary tumors of different histologic types. Using PCR-SSCP, we analyzed exons one (126 bp) and two (307 bp) of the MTS1 gene to determine the incidence of mutation in a population of 50 primary breast adenocarcinomas and corresponding normal tissue. Analysis of five breast tumor cell lines was also performed. We found no mutations in the MTS1 gene in the primary breast tumor samples. One cell line was found to have a homozygous deletion of the gene. Our results suggest that the MTS1 gene is not mutated with increased frequency in primary breast tumors, and thus may not play a major role in breast carcinogenesis.